Brokerages Anticipate Allakos Inc. (NASDAQ:ALLK) to Post -$1.20 Earnings Per Share

Wall Street analysts expect Allakos Inc. (NASDAQ:ALLK) to post ($1.20) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Allakos’ earnings. The highest EPS estimate is ($1.09) and the lowest is ($1.30). Allakos posted earnings of ($0.86) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 39.5%. The firm is scheduled to issue its next earnings report on Monday, March 7th.

According to Zacks, analysts expect that Allakos will report full year earnings of ($4.48) per share for the current fiscal year, with EPS estimates ranging from ($4.55) to ($4.36). For the next financial year, analysts expect that the firm will post earnings of ($5.82) per share, with EPS estimates ranging from ($8.45) to ($4.42). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Allakos.

Allakos (NASDAQ:ALLK) last issued its earnings results on Monday, November 8th. The company reported ($1.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.12) by ($0.04).

ALLK has been the topic of several analyst reports. Zacks Investment Research upgraded shares of Allakos from a “sell” rating to a “hold” rating in a research note on Monday, October 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Allakos in a research note on Monday, October 18th. Finally, Morgan Stanley decreased their price target on Allakos from $88.00 to $86.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 10th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Allakos currently has a consensus rating of “Buy” and a consensus price target of $141.09.

Shares of Allakos stock traded up $1.81 on Thursday, reaching $81.22. 192,026 shares of the company were exchanged, compared to its average volume of 249,443. The business has a fifty day simple moving average of $98.31. Allakos has a fifty-two week low of $75.41 and a fifty-two week high of $157.98. The stock has a market cap of $4.41 billion, a price-to-earnings ratio of -19.67 and a beta of 0.71.

In related news, Director Steven P. James sold 4,000 shares of the company’s stock in a transaction dated Tuesday, September 28th. The shares were sold at an average price of $108.12, for a total transaction of $432,480.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 34.45% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its holdings in Allakos by 9.0% in the third quarter. Bank of New York Mellon Corp now owns 140,495 shares of the company’s stock valued at $14,875,000 after buying an additional 11,644 shares during the period. ArrowMark Colorado Holdings LLC lifted its stake in Allakos by 38.3% in the third quarter. ArrowMark Colorado Holdings LLC now owns 455,660 shares of the company’s stock valued at $48,241,000 after buying an additional 126,086 shares during the period. Strategic Wealth Advisors Group LLC acquired a new position in Allakos in the third quarter valued at about $1,078,000. BNP Paribas Arbitrage SA lifted its stake in Allakos by 383.0% in the third quarter. BNP Paribas Arbitrage SA now owns 6,294 shares of the company’s stock valued at $666,000 after buying an additional 4,991 shares during the period. Finally, Janus Henderson Group PLC lifted its stake in Allakos by 19.7% in the third quarter. Janus Henderson Group PLC now owns 983,329 shares of the company’s stock valued at $104,111,000 after buying an additional 161,606 shares during the period. Institutional investors and hedge funds own 82.70% of the company’s stock.

About Allakos

Allakos, Inc engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis.

Featured Story: How is a price target determined?

Get a free copy of the Zacks research report on Allakos (ALLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Allakos (NASDAQ:ALLK)

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.